# Meniere Disease

Diagnose Meniere disease clinically by recurrent spontaneous vertigo, documented low- to mid-frequency sensorineural hearing loss, and fluctuating unilateral aural symptoms; exclude mimics before escalating from dietary measures to intratympanic or ablative therapy.

**Clinical question:** How should physicians confirm Meniere disease, exclude competing vestibular diagnoses, and select vertigo-directed therapy?

Updated: 2026-08-24T18:16:15.036271+00:00

## What matters in practice
- Definite Meniere disease requires at least two spontaneous vertigo episodes lasting 20 minutes to 12 hours, audiometrically documented low- to mid-frequency sensorineural hearing loss, fluctuating ipsilateral aural symptoms, and no better alternative vestibular diagnosis. [9][13]
- Obtain formal audiometry during the diagnostic evaluation; electrocochleography, VEMP, caloric testing, vHIT, and hydrops MRI can characterize inner-ear dysfunction but do not replace clinical diagnostic criteria. [10][11][13]
- Use MRI or auditory brainstem response selectively to exclude retrocochlear disease when the presentation includes asymmetric sensorineural hearing loss or otherwise raises concern for an alternative lesion. [12][13]
- For persistent disabling vertigo despite conservative management, intratympanic steroid treatment is a hearing-preserving escalation option; intratympanic gentamicin offers vertigo control but carries a hearing-loss tradeoff. [15][16][18][20]
- Reserve destructive procedures such as labyrinthectomy or vestibular neurectomy for intractable disease after noninvasive treatment failure, with hearing status central to procedure selection. [2][17][18]

## Apply clinical criteria before labeling recurrent vertigo as Meniere disease

There is no gold-standard diagnostic test; diagnosis remains clinical with audiometric confirmation. [1][13]

Classify as definite Meniere disease when the patient has at least two spontaneous vertigo episodes lasting 20 minutes to 12 hours; low- to mid-frequency sensorineural hearing loss documented by audiometry in the affected ear at least once during the disease course; fluctuating ipsilateral hearing loss, tinnitus, or aural fullness; and no better explanation. The audiogram is not optional when assigning the definite diagnosis. [9][11][13]

Classify as probable Meniere disease when there are at least two episodes of spontaneous vertigo or dizziness lasting 20 minutes to 24 hours with fluctuating ipsilateral aural symptoms, but the required audiometric hearing-loss documentation is absent. Reassess with serial audiometry if attacks continue or cochlear symptoms fluctuate. [13]

Do not use endolymphatic hydrops on MRI as a stand-alone diagnostic endpoint. Hydrops can occur in vestibular migraine, although it is reported more often in Meniere disease; MRI therefore modifies the differential rather than superseding the clinical syndrome and audiogram. [10]
- Document attack duration, spontaneous versus position-triggered onset, laterality of aural symptoms, and whether hearing changes occur with attacks; these determine whether the patient meets definite or probable criteria. [9][13]
- Repeat pure-tone audiometry when the initial study is nondiagnostic but the history remains strongly suggestive, because hearing loss may fluctuate over the disease course. [9][12][13]
- Avoid diagnosing Meniere disease from tinnitus, fullness, or vertigo alone; the defining diagnostic branch is the combination of episodic vestibular syndrome and ipsilateral cochlear involvement. [9][13]

*Clinical diagnostic categories for Meniere disease. [9][13]*

| Category | Vestibular episode requirement | Cochlear requirement | Next action |
| --- | --- | --- | --- |
| Definite Meniere disease | At least 2 spontaneous vertigo episodes, each 20 minutes to 12 hours. [9][13] | Audiometrically documented low- to mid-frequency SNHL plus fluctuating ipsilateral hearing loss, tinnitus, or fullness. [9][13] | Exclude competing vestibular diagnoses; establish baseline hearing and vertigo burden. [9][13] |
| Probable Meniere disease | At least 2 spontaneous vertigo or dizziness episodes, each 20 minutes to 24 hours. [13] | Fluctuating ipsilateral aural symptoms; audiometric threshold for definite disease not yet documented. [13] | Obtain or repeat audiometry and continue diagnostic reassessment. [13] |
| Not established | Episode duration or trigger pattern is inconsistent, or an alternative disorder better explains symptoms. [9][13] | No characteristic ipsilateral fluctuating cochlear syndrome, or hearing findings direct another evaluation. [9][12][13] | Pursue the competing diagnostic branch rather than escalating Meniere-directed therapy. [9][13] |

## Use episode timing, triggers, neurologic findings, and hearing pattern to redirect the workup

Meniere disease is a diagnosis of exclusion when competing vestibular disorders better account for the syndrome. [9][13]

Vestibular migraine is the most consequential clinical mimic when recurrent vertigo coexists with migraine. Auditory symptoms and even MRI-demonstrated hydrops may occur in vestibular migraine, so a migraine-associated pattern should prevent overreliance on hydrops imaging and prompt reassessment of whether the full audiometric and temporal criteria for Meniere disease are met. [10][13]

Redirect patients with brief position-triggered attacks toward benign paroxysmal positional vertigo, and those with a sustained acute vestibular syndrome toward vestibular neuritis or labyrinthitis rather than Meniere disease. Sudden sensorineural hearing loss, vestibular paroxysmia, drug-induced vertigo, posterior-circulation ischemia, and intracranial mass lesions are additional alternatives explicitly requiring exclusion under diagnostic criteria. [9]

Escalate beyond a peripheral-vestibular attribution when focal neurologic deficits, a central neurologic syndrome, or concern for posterior circulation ischemia is present. In patients with hearing findings or symptoms concerning for retrocochlear pathology, MRI or auditory brainstem response has been used to exclude acoustic neuroma and auditory neuropathy spectrum disorder. [9][12]
- Position-triggered attacks: evaluate for benign paroxysmal positional vertigo rather than treating as a spontaneous Meniere attack. [9]
- Sustained acute vertigo after a single onset: evaluate vestibular neuritis or labyrinthitis rather than applying recurrent-attack criteria. [9]
- Sudden hearing loss: evaluate as sudden sensorineural hearing loss; it is an exclusion diagnosis in the Meniere framework. [9]
- Migraine-associated recurrent vertigo: assess vestibular migraine even if aural symptoms or hydrops MRI are present. [10]
- Asymmetric or retrocochlear concern: obtain MRI or auditory brainstem response to exclude acoustic neuroma or auditory neuropathy spectrum disorder. [12]

*Features that should redirect evaluation away from Meniere disease. [9][10][12][13]*

| Alternative branch | Discriminator | Immediate next step |
| --- | --- | --- |
| Vestibular migraine | Recurrent vertigo with a migraine-associated syndrome; hydrops MRI is not exclusive to Meniere disease. [10] | Apply vestibular-migraine assessment rather than using MRI hydrops alone to confirm Meniere disease. [10][13] |
| Benign paroxysmal positional vertigo | Vertigo is position-triggered rather than spontaneous episodic vertigo. [9] | Perform a positional-vertigo evaluation. [9] |
| Vestibular neuritis or labyrinthitis | Sustained acute vestibular presentation rather than recurrent discrete attacks. [9] | Evaluate for acute peripheral vestibular disease. [9] |
| Central or structural disease | Posterior-circulation ischemia, intracranial lesion concern, or retrocochlear concern. [9][12] | Pursue urgent neurologic assessment when ischemia is suspected; use MRI or auditory brainstem response for selected retrocochlear exclusions. [9][12] |

## Use audiometry for confirmation and ancillary testing for phenotype or exclusion

Testing should answer a specific question: document hearing loss, exclude another lesion, or quantify vestibular function. [10][11][13]

Perform pure-tone audiometry to document the low- to mid-frequency sensorineural hearing loss required for definite disease and to establish a hearing baseline before potentially ototoxic treatment. Audiometric confirmation supports diagnosis, whereas imaging and laboratory studies are primarily used to exclude alternative diagnoses. [9][13]

Consider electrocochleography, cervical or ocular vestibular-evoked myogenic potentials, videonystagmography with caloric testing, video head impulse testing, or rotary-chair testing when the clinical question is vestibular phenotyping or diagnostic clarification. These tests are adjunctive: their diagnostic value remains controversial, and no individual functional test is specific for Meniere disease. [10][11][12]

Hydrops MRI may provide supportive evidence in selected diagnostically difficult cases. A review cited vestibular hydrops MRI as having higher diagnostic value for definite disease than several audiovestibular tests, but technical pitfalls and overlap with vestibular migraine require interpretation in the clinical context. [10][11]
- Before intratympanic gentamicin, document current hearing because gentamicin has a potential hearing-loss risk. [16]
- When serial symptoms and audiograms do not align with the diagnostic criteria, revisit vestibular migraine, positional vertigo, sudden sensorineural hearing loss, central ischemia, and structural lesions rather than ordering ancillary vestibular tests indiscriminately. [9][10][13]
- Use ancillary vestibular studies to supplement, not replace, history, examination, and audiometry. [1][10][12]

*Test selection in suspected Meniere disease. [10][11][12][13]*

| Test | Decision it informs | Interpretive limitation |
| --- | --- | --- |
| Pure-tone audiometry | Documents low- to mid-frequency SNHL required for definite disease and establishes a hearing baseline. [9][13] | A single normal study may not capture fluctuating hearing loss; repeat when clinical suspicion persists. [9][12][13] |
| MRI or auditory brainstem response | Excludes selected retrocochlear alternatives such as acoustic neuroma or auditory neuropathy spectrum disorder. [12] | These studies do not independently establish Meniere disease. [13] |
| Electrocochleography, VEMP, calorics, vHIT, rotary chair | Characterizes cochlear or vestibular dysfunction when clarification is needed. [10][11] | Diagnostic values are controversial and no test is a disease-specific gold standard. [1][12] |
| Hydrops MRI | May support endolymphatic-hydrops assessment in difficult cases. [10][11] | Hydrops can be present in vestibular migraine and requires clinical correlation. [10] |

## Escalate vertigo-directed treatment while preserving hearing when feasible

Treatment selection should track vertigo burden, hearing status, laterality, and failure of less destructive options. [2][16][18]

Start with conservative measures for patients meeting clinical criteria who have nonemergent episodic attacks. Common first-line dietary modification includes reducing sodium, caffeine, and alcohol intake; one review describes sodium intake below 3 g/day as a proposed target, while acknowledging that dietary restriction is commonly advised rather than established by a definitive diagnostic biomarker. [16]

Use vestibular rehabilitation during the intercritical period, not as a substitute for diagnosing an active alternative vestibular syndrome. Consensus material also recommends lifestyle modification and considers psychotherapy as part of conservative care for patients with persistent disease burden. [2]

For frequent or disabling vertigo that remains uncontrolled after conservative treatment, offer intratympanic steroid injection as a nonablative escalation strategy. Intratympanic steroids are described as a relatively safe second-line treatment with less cochleovestibular damage than gentamicin; reported long-term response is heterogeneous, so reassess vertigo frequency and hearing rather than presuming durable control. [15][18][20]

Consider intratympanic gentamicin when vertigo remains intractable and the patient accepts the hearing-preservation tradeoff. Gentamicin can provide substantial vertigo control and is often used as a less invasive alternative to surgery, but it has a potential risk of hearing loss; low-dose or titration strategies have been reported to seek selective vestibular ablation. [8][16][19]

For disease refractory to noninvasive treatment, discuss operative options with an otologist. Endolymphatic sac surgery is a nondestructive surgical option; a cited meta-analysis reported vertigo control in at least 75% of medically refractory patients and approximately 2% worsened hearing, although selection and comparative evidence should be discussed. Vestibular neurectomy and labyrinthectomy are destructive last-line procedures for intractable disease. [2][17][21]
- First-line: reduce sodium, caffeine, and alcohol intake; a sodium target below 3 g/day has been proposed. [16]
- Between attacks: vestibular rehabilitation for intercritical imbalance. [2]
- Persistent disabling vertigo after conservative management: intratympanic steroid injection, particularly when hearing preservation is prioritized. [15][18][20]
- Intractable vertigo with acceptance of ototoxic risk: intratympanic gentamicin, with baseline and follow-up hearing assessment. [8][16][19]
- Failure of noninvasive options: otologic surgical discussion; reserve destructive procedures for last-line treatment. [2][17][18]

### Procedure selection in medically refractory disease

Choose a hearing-preserving pathway before an ablative pathway whenever clinically feasible. Intratympanic steroid therapy and endolymphatic sac surgery are characterized as nonablative options, whereas intratympanic gentamicin, vestibular neurectomy, and labyrinthectomy intentionally carry greater vestibular or cochlear risk. [2][17][18]

If vestibular neurectomy is selected, approach-specific tradeoffs matter: posterior-fossa approaches have been reported to have lower hearing-loss and facial-paralysis rates than a middle-fossa approach, while middle-fossa approaches have lower cerebrospinal-fluid leak rates. [17]
- Endolymphatic sac surgery: nondestructive option after medical-management failure; cited evidence reports at least 75% vertigo control and 2% worsened hearing. [17]
- Vestibular neurectomy: consider only in carefully selected refractory cases after noninvasive failure; counsel on operative approach tradeoffs. [2][17]
- Labyrinthectomy: destructive last-line intervention for intractable disease. [2]

*Vertigo-treatment escalation and dominant tradeoffs in Meniere disease. [2][15][16][17][18][20]*

| Clinical situation | Treatment option | Reason to choose | Key tradeoff or monitoring |
| --- | --- | --- | --- |
| Initial nonemergent disease management | Dietary sodium, caffeine, and alcohol reduction. [16] | Common first-line conservative approach; sodium below 3 g/day has been proposed. [16] | Track attack frequency, functional burden, and hearing trajectory. [16] |
| Intercritical disequilibrium | Vestibular rehabilitation. [2] | Recommended in the intercritical period. [2] | Does not replace reassessment for an alternative diagnosis when the syndrome changes. [2][9] |
| Vertigo persists after conservative treatment; hearing preservation prioritized | Intratympanic steroid injection. [15][18][20] | Nonablative second-line option with less cochleovestibular damage than gentamicin. [15][18] | Long-term response is heterogeneous; monitor vertigo response and hearing. [20] |
| Intractable vertigo after conservative or nonablative therapy | Intratympanic gentamicin. [8][16][19] | Can provide vertigo control without a more invasive surgical procedure. [8] | Potential hearing loss; obtain baseline and follow-up audiometry. [16] |
| Refractory disease after noninvasive options | Endolymphatic sac surgery, vestibular neurectomy, or labyrinthectomy. [2][17][21] | Surgical escalation for medically refractory disease. [2][17] | Sac surgery is nondestructive; neurectomy and labyrinthectomy are destructive last-line choices. [2][17][18] |

## Measure both vertigo control and hearing preservation over time

Attack reduction and hearing preservation may diverge, particularly after ablative therapy. [16][17][22]

At follow-up, record vertigo-attack frequency, attack duration, functional disability, interval imbalance, tinnitus or fullness, and repeat audiometry when hearing symptoms change or after hearing-risk interventions. This is especially important after intratympanic gentamicin because vertigo benefit must be weighed against potential hearing loss. [8][16]

Counsel that the natural history can change: attacks may become less frequent while hearing loss and tinnitus become permanent. In an untreated cohort cited in a review, complete vertigo control occurred in 57% at 2 years and 71% after a mean 8.3 years; this spontaneous improvement complicates attribution of benefit in uncontrolled interventions. [23]

Escalate treatment based on ongoing disabling vertigo rather than hearing loss alone. Conversely, progressive or asymmetric auditory findings should trigger reconsideration of alternative diagnoses and selective MRI or auditory brainstem response evaluation rather than automatic progression to destructive therapy. [12][13]
- Use serial audiometry to monitor fluctuating or progressive hearing loss and to document post-gentamicin cochlear risk. [9][16]
- After intratympanic steroid injection, reassess for nonresponse because long-term benefit is variable. [20][22]
- Before destructive surgery, verify that the diagnosis remains clinically secure and that noninvasive options have failed. [2][9][18]
- Recognize that reduced vertigo frequency does not necessarily represent preserved cochlear function; continue hearing-focused follow-up. [23]

*Monitoring priorities by treatment phase. [8][16][20][23]*

| Phase | Measure | Action triggered by result |
| --- | --- | --- |
| Baseline | Pure-tone audiometry, attack frequency and duration, functional burden. [9][13] | Confirm diagnostic category and establish hearing-preservation priorities before escalation. [9][13] |
| After conservative management | Frequency of disabling vertigo and interval imbalance. [2][16] | Persistent disabling attacks support consideration of intratympanic steroid treatment. [18][20] |
| After intratympanic steroid | Vertigo response and repeat hearing assessment when symptoms change. [20][22] | Nonresponse or recurrent disabling attacks prompts reassessment and discussion of further escalation. [20] |
| After intratympanic gentamicin | Vertigo control and serial hearing status. [8][16] | Hearing deterioration requires reconsideration of additional ototoxic or destructive treatment. [16] |

## References
1. Diagnostic and therapeutic strategies for Meniere's disease of the Japan Society for Equilibrium Research — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0385814620302777
2. International consensus (ICON) on treatment of Ménière's disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1879729618300024
3. Committee on Hearing and Equilibrium Guidelines for the ... — aao-hnsfjournals.onlinelibrary.wiley.com — https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1016/S0194-5998%2895%2970102-8
4. Meniere's disease: Pathogenesis, treatments, and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0013935123017760
5. Identifying Predictors of Treatment Response in Meniere's ... — aao-hnsfjournals.onlinelibrary.wiley.com — https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1002/ohn.486
6. Meniere's disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0140673608611617
7. Meniere’s disease: an evidence based approach to assessment and management - Syed - 2012 - International Journal of Clinical Practice - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2011.02842.x
8. Intratympanic Gentamicin Therapy for Meniere's Disease : Otology & Neurotology — journals.lww.com — https://journals.lww.com/otology-neurotology/fulltext/1997/01000/intratympanic_gentamicin_therapy_for_meniere_s.8.aspx
9. The diagnostic significance and value of vestibular function testing combined with MRI in Meniere’s disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12713301
10. Functional and Molecular Markers for Hearing Loss and Vertigo Attacks in Meniere’s Disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9916751
11. A bibliometric and visualization study of Meniere's disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9997775
12. Characteristics of the Cochlear Symptoms and Functions in Meniere's Disease - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5072257
13. Meniere Disease - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK536955
14. Meniere Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK536955
15. Intratympanic steroid versus gentamicin for treatment of ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/34098455
16. Dietary Restriction for The Treatment of Meniere’s Disease - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265917
17. Vestibular neurectomy for Meniere’s Disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1043181016300549
18. Meniere's disease: Medical management, rationale for vestibular preservation and suggested protocol in medical failure - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196070920305111
19. Surgical management of Meniere’s disease in the era of gentamicin — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0194599804021138
20. Differences in responsiveness of intratympanic steroid injection for intractable vertigo in Meniere's disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196070921002428
21. Endolymphatic sac-vein decompression for intractable meniere’s disease: long term treatment results - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0194599803000846
22. Treatment of Meniere’s disease with intratympanic dexamethazone plus high dosage of betahistine - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196070915002471
23. Menière's disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/B9780444634375000194
24. Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196070914002622

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.